Antagonists of myostatin, a blood-borne negative regulator of muscle growth produced in
muscle cells, have shown considerable promise for enhancing muscle mass and strength in …

Gene-targeted therapies, such as adeno-associated viral vector (AAV)-mediated gene
therapy and cell-mediated therapy using myogenic stem cells, are hopeful molecular …

In most cases, pharmacologic strategies to treat genetic muscle disorders and certain
acquired disorders, such as sporadic inclusion body myositis, have produced modest …

Recovery from skeletal muscle injury is often incomplete because of the formation of fibrosis
and inadequate myofiber regeneration; therefore, injured muscle could benefit significantly …

Introduction: ACE‐083 is a locally acting follistatin‐based therapeutic that binds myostatin
and other muscle regulators and has been shown to increase muscle mass and force in …

Background Myostatin antagonists are being developed as therapies for Duchenne
muscular dystrophy due to their strong hypertrophic effects on skeletal muscle. Engineered …

Myostatin is a transforming growth factor-β family member that acts as a negative regulator
of skeletal muscle mass. To identify possible myostatin inhibitors that may have applications …

Follistatin (FST) is a member of the tissue growth factor β family and is a secreted
glycoprotein that antagonizes many members of the family, including activin A, growth …

Myostatin is a TGF-β family member that normally acts to limit skeletal muscle mass.
Follistatin is a myostatin-binding protein that can inhibit myostatin activity in vitro and …

Follistatin is essential for skeletal muscle development and growth, but the intracellular
signaling networks that regulate follistatin-mediated effects are not well defined. We show …